Device Industry Attorneys Criticize FDA's Emerging Signals Draft Guidance
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration's 'emerging signals' draft guidance, released Dec. 31, is drawing criticism from medical device industry lawyers and advocates who complain it will unfairly cast a negative light on some medtech products, will lower beneficial use of devices and provide fodder for product liability suits.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.